The company has not filed an annual or quarterly report since its FY2021 20-F, filed Jun 28, 2022. Its latest SEC filing is a SC 13G/A from Feb 10, 2023.
20-F for FY2021, filed Jun 28, 2022
The sections below describe the company as of the FY2021 annual report.
Developed arimoclomol, a treatment candidate for Niemann-Pick disease type-C, and sold it through a French early-access program.
20-F for FY2021, filed Jun 28, 2022
Orphazyme sold arimoclomol through a service agreement with Clinigen Health Limited, which held the drug on consignment until it was transferred to third-party customers.
20-F for FY2021, filed Jun 28, 2022
Loading...
